Steven Pieper - 31 Jan 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2024
Net transactions value
$0
Form type
4
Filing time
31 Jan 2024, 17:05:28 UTC
Previous filing
21 Nov 2023
Next filing
26 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +450,000 +38% $0.000000 1,626,912 31 Jan 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.

Remarks:

Chief Financial Officer